source
- CSL agrees $355M upfront deal to co-develop Alentis anti-fibrosis drug for kidney and liverCSL, an Australian drugmaker, announced a partnership with Alentis Therapeutics that includes a $355 million upfront payment. Under the agreement, CSL will co-develop Alentis's anti-fibrosis candi…
- FDA delays review of Novo's hemophilia A drug denecimig over factory issuesUS regulators have extended the review of Novo's hemophilia A injection, denecimig, because of problems at an unnamed manufacturing facility. The FDA said ongoing remediation activities observed d…